The use of the protein UK 114 for inhibiting organ transplant rejection

专利摘要:
The protein UK 114 is used to reduce or inhibit the rejection of organ grafts, and to provide a method for preparing a drug that maintains the compliance of the graft itself.
公开号:KR20020020745A
申请号:KR1020017016409
申请日:2000-06-19
公开日:2002-03-15
发明作者:바르토렐리알베르토；파네라이알베르토；니코레띠피에르페르디난도
申请人:스피니엘로 살바토르；제테시스 에스.피.아.；
IPC主号:

专利说明:

The use of the protein UK 114 for inhibiting organ transplant rejection
[2] The ongoing development of surgical techniques, along with the development of more selective and effective immunosuppressive agents, has gradually improved the outcome of organ transplantation.
[3] However, organ transplantation, which is presented as a fundamental solution in the case of terminal organ failure, has a serious problem of practically rejection. In order to control such a problem, an immunosuppressive agent is used to treat such organs. However, infectious complications still result in death of organ transplant patients. Moreover, treatment with immunosuppressants can never be stopped after the acute rejection has been resolved, and maintenance therapy should continue indefinitely even with relatively low doses.
[4] Rejection can also occur in allografts (between genetically different individuals in the same species) due to cell-mediated or humoral immune responses to histocompatibility antigens (HLA) on organ donor cell membranes.
[5] The cellular immune response is characterized by disrupting the graft several days or months after transplantation and causing progressive infiltration of monocytes (macrophages, lymphocytes and monocytes) in the transplanted tissue; If the cells recognize antigen differences, they destroy the graft by activating T lymphocytes that stimulate both cellular (T cell) and humoral (B cell) immune responses. The aforementioned cell mediated rejection response can often be treated with potent immunosuppressive therapy. If treated, no new acute rejection will occur, and if allografts will usually survive for a long time.
[6] The role of humoral antibodies in rejection is evident when a patient who has been transplanted is presensitized to the HLA antigen present in the graft: in this case, the transplanted organ is within hours or even minutes after blood vessel regeneration. Destroyed (superacute rejection).
[7] Chronic rejection refers to a gradual exacerbation and failure process that occurs later in life of the graft over months to years. The immunological mechanism of chronic rejection is not very clear. Its histological image differs from acute rejection and is mainly characterized by lesions on the arterial endothelium, which expands proliferatively on the arterial endothelium, gradually leading to fibrosis, ischemia and vascular lumen occlusion of the graft.
[8] Immunosuppressive therapies that control long-term rejection currently use corticosteroids, azathioprine (or cyclophosphamide in patients who do not tolerate azathioprine) and cyclosporin, usually using a combination thereof.
[9] However, each of these drugs contains many unwanted side effects, which can be summarized as follows:
[10] Corticosteroids: diabetes mellitus, increased protein catabolism, adrenal cortex contraction, decreased response of connective tissue to lesions, myopathy, osteoporosis, hematopoietic and nervous system effects;
[11] Azathioprine: decreased bone marrow, hepatitis;
[12] Cyclophosphamide: nefrotoxicity;
[13] Cyclosporin: neprotoxicity, hepatotoxicity, refractory hypertension and tumor growth.
[14] Thus, there is a clear need for other therapies that inhibit or reduce rejection of transplanted organs or tissues, or increase graft compliance in transplanted patients without the aforementioned side effects.
[1] The present invention relates to a method for using protein UK 114 to reduce or inhibit rejection of transplanted organs as well as to maintain compliance with the graft.
[15] In SDS-PAGE, a protein labeled UK 114 (disclosed in WO 97/30154 and WO 96/02567), obtained from mammalian liver by an extraction method using perchloric acid with a molecular weight of about 14 kDa, rejects allografts. It has been found that not only can reduce or suppress the response but also maintain the compliance of the graft itself without causing side effects seen with conventional immunosuppressive agents, which is an object of the present invention.
[16] The protein UK 114 acts in the immune system, possibly showing a pleiotropic effect due to the control of cytokine productivity by T cells and macrophages.
[17] According to the invention, the protein UK 114 by extraction or recombination can be administered parenterally, for example intramuscularly, intravenously, intraperitoneally, subcutaneously or sublingually.
[18] Preferred formulation forms are in the form of injections, such as solutions or suspensions, sterile powders for the preparation of injectable solutions or suspensions; Or in solid form such as a sublingual tablet.
[19] Proteins of the present invention may be optionally administered in combination with conventional immunosuppressive agents, corticosteroids, azathioprine, cyclophosphamide, cyclosporine, or mixtures thereof.
[20] Dosage depends on various factors, such as the type of organ or tissue transplanted or to be transplanted, as well as the individual characteristics of the patient (such as body weight). Generally, however, the dosage of UK 114 varies from 0.1 to 30 mg / kg / day for 1 to 6 months after transplantation. Thereafter, maintenance therapy is performed.
[21] Dosage methods such as dosage, route of administration, duration of onset and maintenance therapy, and the possibility of administering a known immunosuppressant or chemotherapeutic agent simultaneously or separately will be determined by a clinician of ordinary skill in the art.
[22] The following examples illustrate the invention in more detail.
[23] Islet transplantation into mouse
[24] After 400 to 500 islet islands were obtained from 5 to 6 week old eulycemic NOD mice (Charles, Calco, Italy) (Mellgren A. et al., Diabetologia, 1986, 29: 670). According to the method described in the recent (7-4 days) female NOD mice with spontaneous diabetes mellitus transplanted under the kidney membrane. This procedure allows NOD mice to recover normal blood glucose and then destroys the islets transplanted within 6 to 8 days so that hyperglycemia recurs (see Sandberg JO et al., Clin. Exp. Immunol., 1997, 108). : 314).
[25] Treatment with UK 114
[26] Every day during the experiment, starting two days prior to transplantation, three groups (15 / group) of diabetic NOD mice from 2 to 25 weeks of age were treated with UK 114 30 or 60 μg / mouse (0.1 or 0.2 ml), or 0.2 ml of PBS. Was administered intraperitoneally. Blood glucose levels were measured from tail blood samples of each animal on days 3, 6, 9, 12 and 14 of transplantation (ExacTech, Baxter Travenol, Deerfield, IL). After 6 hours, when the blood glucose level was 11.8 mmol / l or more, the animal was determined to be diabetic.
[27] During the experiment, one of the control animals and one of the groups that received a small amount of UK 114 died 2 and 3 days after transplantation, which were not included in the data.
[28] On day 3 of the experiment, 5/14 of the PBS-administered controls were still normal blood glucose, on day 6 only one mouse in this group was normal blood glucose, and on day 9 the mean blood glucose level (SD) of all animals was 16.2 ± 3.2 mmol / l. Hyperglycemia, and the mean value increased further to 18.9 ± 4.5 on day 14 (see Table 1).
[29] In contrast, administration of UK 114 inhibited the recurrence of hyperglycemia in transplanted NOD mice according to dose. Of animals treated with 30 μg of UK 114, 12 out of 14 were normal blood glucose on day 6 and 11 out of 14 were normal on days 9 and 14 (see Table 1). Of the 15 animals given higher doses of UK 114, none of the rats had diabetes in 14 days after transplantation (see Table 1).
[30] These data show that administration of UK 114 may inhibit or to some extent prolong the rejection of islet in well-known animal models, thereby suppressing the rejection of transplanted islet with IDDM patients. It suggests potential availability.
[31] Elapsed days36914 PBS9 out of 14 dogs ^a diabetes13 out of 14 diabetes mellitus onset ^d 14 of the 14 horses diabetes ^d 14 of the 14 horses diabetes ^dUK 11430 μg2 out of 14 diabetes mellitus onset ^b 3 out of 14 diabetes mellitus onset ^c 3 out of 14 diabetes mellitus ^e 3 out of 14 diabetes mellitus ^eUK 11460 µg0 out of 15 diabetes mellitus onset ^c 0 out of 15 diabetes onset ^f 0 out of 15 diabetes onset ^f 0 out of 15 diabetes onset ^f
[32] b vs a, P = 0.02 in chi-square distribution
[33] c vs a, P <0.0001 in chi-square distribution
[34] e, f, vs d, P <0.0001 in chi-square distribution

权利要求:
Claims (3)
[1" claim-type="Currently amended] Using a protein UK 114 to reduce or inhibit rejection of the transplanted organ and to prepare a drug that maintains compliance with the transplanted organ itself.
[2" claim-type="Currently amended] The method of claim 1, wherein the protein UK 114 is used to prepare a drug that reduces or inhibits rejection of Langerhans cell grafts.
[3" claim-type="Currently amended] Protein UK 114, characterized in that it is an anti-rejection agent.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US5783216A|1998-07-21|Methods for inhibiting rejection of transplanted tissue

---

EP0725648B1|2007-05-02|Hepatoselective pharmaceutical actives

---

Starzl et al.1980|The use of cyclosporin A and prednisone in cadaver kidney transplantation

---

AU659419B2|1995-05-18|Method of treating or preventing type 1 diabetes by oral administration of insulin

---

FI120696B|2010-01-29|A method for increasing cellular recovery and proliferation

---

ES2276392T3|2007-06-16|In vitro growth of functional islands of langerhans and in vivo uses of the same.

---

Schoenberg et al.1990|Oxygen free radicals in acute pancreatitis of the rat.

---

US5637309A|1997-06-10|Physiologically active substance-prolonged releasing-type pharmaceutical preparation

---

AU776514B2|2004-09-09|Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof

---

Unger1978|Role of glucagon in the pathogenesis of diabetes: the status of the controversy

---

JP4751493B2|2011-08-17|Methods of blocking immune responses by blocking the GP39 / CD40 and CTLA4 / CD28 / B7 pathways and compositions used therefor

---

EP0893996B1|2002-09-18|Use of a rapamycin derivative in vasculopathies and xenotransplantation

---

EP2094839B1|2020-02-05|Expansion of hematopoietic stem cells

---

EP1012188B1|2004-08-18|Composition for treating diabetes mellitus and obesity

---

ES2312820T3|2009-03-01|Paramycin and il-10 for the treatment of autoimmune diseases.

---

US7347999B2|2008-03-25|Methods of treatment of hematopoietic disorders

---

EP0639079B1|2000-01-12|Methods for treating interleukin-1 and tumor necrosis factor mediated diseases

---

JP5590624B2|2014-09-17|Prolonging allograft survival by inhibiting complement activity

---

EP1837031B1|2009-10-14|Compositions and methods for treating diabetes

---

EP0438526B1|1994-09-14|Method for the treatment of grafts prior to transplantation

---

AU2001286221B2|2006-09-28|Remedies for ischemic diseases

---

Cornelius et al.1997|In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas

---

US7067489B2|2006-06-27|Hematopoietic stimulation

---

Todo et al.1990|Liver, kidney, and thoracic organ transplantation under FK 506.

---

ES2253353T3|2006-06-01|Serico cholesterol reduction.

同族专利:

---

公开号 | 公开日

---

HU0201796A3|2005-01-28|

---

MXPA01013238A|2002-07-02|

---

HU0201796A2|2002-09-28|

---

DK1194158T3|2004-06-07|

---

ITMI991384A1|2000-12-22|

---

ZA200110213B|2002-12-12|

---

EP1194158B1|2004-01-28|

---

TR200103748T2|2002-05-21|

---

WO2000078329A2|2000-12-28|

---

JP2003502380A|2003-01-21|

---

AU774065B2|2004-06-17|

---

NO20016326D0|2001-12-21|

---

AT258443T|2004-02-15|

---

RU2001134605A|2003-08-27|

---

PT1194158E|2004-04-30|

---

NZ516159A|2003-07-25|

---

WO2000078329A3|2001-04-19|

---

CA2377639A1|2000-12-28|

---

NO20016326L|2001-12-21|

---

BR0011832A|2002-03-05|

---

PL353003A1|2003-09-22|

---

CZ20014631A3|2002-04-17|

---

ITMI991384D0|1999-06-22|

---

DE60007991D1|2004-03-04|

---

ES2213020T3|2004-08-16|

---

AU5221700A|2001-01-09|

---

IL147223D0|2002-08-14|

---

CN1399555A|2003-02-26|

---

DE60007991T2|2004-12-09|

---

EP1194158A2|2002-04-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1999-06-22|Priority to IT1999MI001384A

---

1999-06-22|Priority to ITMI99A001384

---

2000-06-19|Application filed by 스피니엘로 살바토르, 제테시스 에스.피.아.

---

2000-06-19|Priority to PCT/EP2000/005621

---

2002-03-15|Publication of KR20020020745A

优先权:

---

申请号 | 申请日 | 专利标题

---

IT1999MI001384A|ITMI991384A1|1999-06-22|1999-06-22|Use of the protein UK 114 for inhibiting the rejection of organ transplants|

---

ITMI99A001384|1999-06-22|

---

PCT/EP2000/005621|WO2000078329A2|1999-06-22|2000-06-19|The use of the protein uk 114 for inhibiting organ transplant rejection|